GVGH iNTS-TCV is under clinical development by GSK and currently in Phase II for Salmonella typhi Infections. According to GlobalData, Phase II drugs for Salmonella typhi Infections have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GVGH iNTS-TCV’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GVGH iNTS-TCV overview
iNTS-TCV is under development for the prevention of invasive nontyphoidal salmonellosis (iNTS) and typhoid fever. The vaccine candidate is a trivalent iNTS-typhoid conjugate vaccine (TCV). It is administered through intramuscular route and is being developed based on GMMA technology.
GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
For a complete picture of GVGH iNTS-TCV’s drug-specific PTSR and LoA scores, buy the report here.